Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Horizon Discovery strikes immuno-oncology JV

Horizon Discovery is to form a new joint venture called Avvinity Therapeutics in a bid to target an immuno-oncology market currently worth £25bn a year.
Horizon Discovery strikes immuno-oncology JV
The new venture is targeting an immuno-oncology market currently worth £25bn a year

Horizon Discovery (LON:HZD) is to form a new joint venture called Avvinity Therapeutics in a bid to target an immuno-oncology market currently worth £25bn a year.

The venture is with UK based biotech Centauri Therapeutics and will combine Horizon's gene editing, immunology, oncology and drug discovery capabilities with Centauri's Alphamer technology to  develop therapeutics for solid tumours and leukaemias.

Dr Darrin M. Disley' chief executive of Horizon, told investors: "By combining Horizon's deep understanding of the genetic basis of cancer alongside its gene editing, drug discovery and emerging immuno-oncology toolbox, with Centauri's unique Alphamer technology and knowledge of its use, we have created an exciting new company to spearhead Horizon's move into targeted therapeutic development."

Under the terms,  Horizon will out-license certain intellectual property (IP) relating to its translational genomics and drug discovery platforms, and will invest up to £5.3 million over two tranches.

The first tranche  of £2.5mln has been committed, and the second will be at Horizon's discretion pending the progress of three development programmes.

Centauri will license background IP and expertise on its Alphamer technology to Avvinity, which will have exclusivity for the field of oncology for an initial three years, which can be extended.

Neither Horizon nor Centauri have to provide further funding to Avvinity, though both may choose to participate in future funding rounds. Subject to achieving key development milestones, Avvinity plans to raise new external investment to take its innovative drugs into clinical trials, at which time the value of Horizon's stake in the business would be highly-material, the firm pointed out.

The move is part of Horizon's strategy to invest up to £10 million, further leveraged by its IP, technology platforms and know-how, to identify the next generation of molecular and cellular cancer therapeutics.

MF

View full HZD profile View Profile

Horizon Discovery Group PLC Timeline

Related Articles

biotech2.jpg
August 18 2017
The company operates a hybrid model, which means its revenues come from providing antibody research and engineering services and creating drug conjugates (targeted treatments for diseases such as cancer). It also manufactures antibodies and proteins for clinical studies
mri scanner
July 24 2017
The Assessa PML platform is designed to facilitate the remote transfer, management and storage of MRI scans to help doctors detect progressive multifocal leukoencephalopathy
scientist in a lab
September 27 2017
“I strongly believe that ValiRx and its assets offer investors or joint venture partners an increasingly attractive and investable proposition as we strengthen our position among frontrunners in the fields of personalised and precision medicine"

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use